Get the Stockscreener App
28.71
0.70%
0.20
Pre-market:
28.71
Janux Therapeutics Inc stock is traded at $28.71, with a volume of 911.78K.
It is up +0.70% in the last 24 hours and up +17.47% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
See More
Previous Close:
$28.51
Open:
$28.1
24h Volume:
911.78K
Relative Volume:
1.02
Market Cap:
$1.73B
Revenue:
$439.00K
Net Income/Loss:
$-105.64M
P/E Ratio:
-15.95
EPS:
-1.8
Net Cash Flow:
$-60.70M
1W Performance:
+15.30%
1M Performance:
+17.47%
6M Performance:
-13.52%
1Y Performance:
-46.82%
1-Day Range:
$27.80
$29.02
1-Week Range:
$25.34
$31.59
52-Week Range:
$21.73
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
28.71 | 1.71B | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-10-25 | Initiated | Stifel | Buy |
| Sep-10-25 | Initiated | Truist | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-11-25 | Initiated | Raymond James | Outperform |
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
Is Janux Therapeutics Inc. stock a safe buy before earningsEarnings Overview Report & Low Drawdown Trading Techniques - newser.com
What analysts say about Janux Therapeutics Inc stockTechnology Stock Trends & Turn Data into Profits With Our Strategies - earlytimes.in
AlphaQuest LLC Has $224,000 Stock Holdings in Janux Therapeutics, Inc. $JANX - MarketBeat
Is Janux Therapeutics Inc. stock attractive for income investorsJuly 2025 Chart Watch & Precise Entry and Exit Recommendations - newser.com
Can Janux Therapeutics Inc. stock surprise with earnings upsideJuly 2025 PreEarnings & Growth Focused Entry Point Reports - newser.com
Will Janux Therapeutics Inc. price bounce be sustainable2025 Top Decliners & Consistent Return Investment Signals - newser.com
Insider Selling: Janux Therapeutics (NASDAQ:JANX) Insider Sells 16,665 Shares of Stock - MarketBeat
Janux Therapeutics Inc expected to post a loss of 62 cents a shareEarnings Preview - TradingView
Using fundamentals and technicals on Janux Therapeutics Inc.New Guidance & Capital Efficiency Focused Strategies - newser.com
What the Next Quarters Forecast Means for Zenith Exports Limited InvestorsIndustrial Stocks Review & High Profit Growth Stocks - earlytimes.in
Volume spikes in Janux Therapeutics Inc. stock – what they meanMarket Sentiment Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
Exit strategy if you’re trapped in Janux Therapeutics Inc.Quarterly Market Review & Precise Trade Entry Recommendations - newser.com
Insider Sell: Andrew Meyer Sells Shares of Janux Therapeutics In - GuruFocus
Janux therapeutics CBO Meyer sells $500k in shares By Investing.com - Investing.com Canada
Janux Therapeutics: The Rumor Mill Spins Up Again (NASDAQ:JANX) - Seeking Alpha
Janux Therapeutics (JANX) Moves 8.8% Higher: Will This Strength Last? - Yahoo Finance
Janux Therapeutics (JANX) Projected to Post Earnings on Wednesday - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Shares Up 8.6%Should You Buy? - MarketBeat
Exclusive BAC Article: Janux Therapeutics; 2nd Half Of 2025 JANX007 mCRPC Results Along With JANX008 In Metastatic Solid Tumors And Catalysts (NASDAQ:JANX) - Seeking Alpha
Is Janux Therapeutics Inc. stock positioned for long term growthJuly 2025 Movers & AI Powered Trade Plan Recommendations - fcp.pa.gov.br
Janux Therapeutics stock gains amid renewed takeover speculation - Seeking Alpha
Can Janux Therapeutics' Upcoming Immunotherapy Updates Drive A Stock Rebound? - RTTNews
Janux Therapeutics Advances with Promising Study on JANX008 for Solid Tumor Treatment - TipRanks
Janux Therapeutics Advances Prostate Cancer Study with JANX007 - TipRanks
Published on: 2025-10-27 07:20:07 - newser.com
Published on: 2025-10-26 21:20:10 - newser.com
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):